PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS Real world ischaemic event reduction with PCSK9i mAbs Inclisiran role in plaque stabilisation Discontinuing PCSK9i leads to increased MACE V-MONO trial of inclisiran monotherapy meets primary endpoints

Podcasts

Can we improve FH detection: Learning from the Dutch

This programme is discussed by Dr Peter Lansberg of the Department of Vascular Medicine at the Academic Medical Center, Amsterdam. He is the founder and former Director of the Dutch National FH Cascade Screening Programme. Dr Lansberg suggests that there are lessons for other countries…

Posted on 2 July 2015 | Posted by Peter Lansberg | Posted in Podcasts

‘Game changing’ management of LDL-C

Professor Steven Nicholls, Professor of Cardiology at the University of Adelaide, Australia, explores the future management of patients with elevated low density lipoprotein cholesterol (LDL-C) and the new treatment options which will be available to clinicians.

Posted on 18 June 2015 | Posted by Steve Nicholls | Posted in Podcasts

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters